Fibrosis is the body process in which excess fibrous connective tissue is formatted in the organ or tissue in repetitive way. Fibrosis may be resulted by specific injuries or diseases. Kidney fibrosis is the common pathway for the chronic kidney disease (CKD) or end-stage kidney diseases (ESRD). Kidney fibrosis is caused by the excessive formation of the extracellular matrix, which is the common phenomenon caused by each type of CKD. Currently, kidney fibrosis market is facing lucrative growth owing to rising incidences of CKDs and renal fibrosis. Increasing patients’ base may promote the future growth of this market.
It is observed that any type of disease, leading to chronic kidney disorder (CKD), may further progress in renal fibrosis. Obesity accelerate the incidence of kidney fibrosis, additionally, habits such as smoking may promote the growth of kidney fibrosis. Geographically, North America would be the lucrative market owing to the wide patient base suffering from CKDs. As per the Centers for Disease Control and Prevention (CDC), ~20 million people are suffering from various types of CKDs of different severity level in 2014. CDC also elaborates that, ~113,136 people in the United States initiated their treatments for end-stage kidney diseases (ESRD) in 2011. The market will be driven by rising health awareness and health concerns among various population groups. However, stringent regulatory approvals related with kidney fibrosis therapeutics may hinder the market growth. Recent technological breakthrough for example, point-of-care drug delivery systems would be the growth opportunities in this market.
The Kidney fibrosis market is segmented based on therapeutics, location of testing, and geography. Based on the type of treatment, the market is further segmented into Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Pirfenidone, Renin Inhibitors and Vasopeptidase Inhibitors. Based on the location of testing, the market is segmented into hospital, clinic, and home treatments. Currently, hospitals perform a majority of tests and would continue to hold a larger market share, both in terms of volume and revenue of the treatments. Geographically, the global Kidney Fibrosis Treatment Market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
Some of the key players working in the kidney fibrosis treatment market include Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, InterMune Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, BioLine Rx Ltd among others.
KEY MARKET SEGMENTS
The market is segmented based on the type of treatments, location of testing, and by the geography.
KIDNEY FIBROSIS TREATMENT MARKET BY THERAPEUTICS
KIDNEY FIBROSIS TREATMENT MARKET BY LOCATION OF THERAPEUTICS
KIDNEY FIBROSIS TREATMENT MARKET BY GEOGRAPHY
SIMILAR MARKET STUDIES
Artificial Intelligence in Healthcare Market by Offering (Hardware, Software, and Services), Technology (Deep Learning, Querying Method, Natural Language Processing, and Context Aware Processing), Application (Robot-assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Dosage Error Reduction, Clinical Trial Participant Identifier, Preliminary Diagnosis, and Others), and End User (Healthcare Provider, Pharmaceutical & Biotechnology Company, Patient, and Payer) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Artificial intelligence assists the machines to perform any task without human interventions. It uses different algorithms and software that help the machine to inculcate perception and reasoning for various situations. AI is widely applicable in the healthcare sector for various purposes such as drug discovery and precision medicine. In addition, ...
July 2017 | $5370 | View Details >>
The Global Ursodeoxycholic Acid market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Ursodeoxycholic Acid in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and ...
July 2017 | $4960 | View Details >>
The Ursodeoxycholic Acid market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include ICE Grindeks ...
July 2017 | $3360 | View Details >>
The Global Ursodeoxycholic Acid market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Ursodeoxycholic Acid in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, ...
July 2017 | $4960 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research